# LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct01828099/  
OnCo record `nct01828099` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ceritinib, Pemetrexed, Cisplatin and Carboplatin in Non-small-cell lung cancer, run by Novartis Pharmaceuticals, completed.

## Summary

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT01828099 by Novartis Pharmaceuticals, with 376 participants recorded, started 2013-07-09 and reaching its primary completion in 2016-06-24. Interventions recorded: Ceritinib, Pemetrexed, Cisplatin, Carboplatin. Conditions recorded: Non-Small Cell Lung Cancer.

Linked to the drug Ceritinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01828099
- Phase: 3
- Setting: A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 376

## Sources

- ClinicalTrials.gov NCT01828099: https://clinicaltrials.gov/study/NCT01828099

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Ceritinib](https://onco.cc/drugs/ceritinib/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct01828099.json